Every Form 4 that Guided Thera (GTHP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GTHP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GTHP filings page.
Guided Therapeutics Inc. director and 10% owner Richard P. Blumberg reported a series of equity restructurings and conversions. He entered an exchange agreement in February 2026 under which 1,000,000 warrants with a $0.50 exercise price were exchanged for 1,000,000 warrants at $0.20 and immediately exercised for $200,000, delivering 1,000,000 shares of common stock.
In the same agreement, the expiration of 1,000,000 warrants with a $0.65 exercise price was extended to September 1, 2027, while 900,000 warrants at $0.30 issued in 2023 expired unexercised on March 1, 2026. On March 26, 2026, Blumberg converted 260 shares of Series F preferred stock into 1,040,000 common shares and 88 shares of Series F‑2 preferred into 352,000 common shares, and also received additional common shares as payment of accrued dividends at a conversion price of $0.2773 per share.
He was also granted 110,000 stock options with a $0.29 exercise price expiring in 2036, with vesting through March 10, 2029. One transaction line shows direct ownership of 10,391,311 common shares following these events.
GUIDED THERAPEUTICS INC director Alan Grujic received a grant of stock options covering 110,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on March 9, 2036, providing potential future equity if exercised.
According to the vesting terms, one-fourth of the options vested on March 10, 2026. The remaining options will vest in monthly installments starting on June 10, 2026, subject to Grujic’s continued service, until fully vested on March 9, 2029. This filing reflects a compensation-related award rather than an open-market purchase or sale.
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several equity-related transactions. On March 31, 2026, he converted $11,019.18 outstanding under a Convertible Promissory Note into 157,417 shares of common stock at a $0.07 conversion price, while $110,000 of principal remains outstanding and is still convertible under the note’s terms.
On March 26, 2026, he converted 10 shares of Series F preferred stock into 40,000 common shares, and also received 2,157 common shares as payment of accrued dividends on that preferred stock at a $0.2773 conversion price. After these transactions, his direct common stock holdings increased to 21,252,673 shares.
Separately, on March 10, 2026, Imhoff was granted 110,000 stock options for common stock at a $0.29 exercise price. One-fourth vested on March 10, 2026, with the remainder vesting monthly starting June 10, 2026 until fully vested on March 10, 2029.
GUIDED THERAPEUTICS INC director James Michael C received a grant of stock options covering 110,000 shares of common stock. The options have an exercise price of $0.29 per share and expire on March 9, 2036.
According to the vesting terms, one-fourth of the options vested on March 10, 2026. The remaining options will vest in monthly installments starting on June 10, 2026, subject to his continued service, until full vesting on March 10, 2029. After this grant, he holds 110,000 stock options directly as reported in this filing.
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several stock-accretive transactions. He converted portions of a September 25, 2025 convertible promissory note into 195,460, 312,720 and 156,086 shares of common stock at a conversion price of $0.07 per share, turning principal and accrued interest into equity.
Imhoff also converted 100 shares of Series E preferred stock with a stated value of $1,000 and a $0.25 conversion price into 400,000 common shares, and received additional common shares for accrued Series E dividends. During February 2026, he exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000, while extending the expiration of 500,000 warrants at $0.65 by one year. Following the latest reported transactions, he directly holds 21,053,099 shares of common stock.
Guided Therapeutics Inc. director James Michael C reported warrant exchanges and an exercise involving the company’s common stock. In February 2026, he exchanged 100,000 warrants with a $0.65 exercise price for 100,000 new warrants with a $0.25 exercise price, then exercised the new warrants for $25,000, receiving 100,000 common shares. As part of the same agreement, the expiration date of separate 4‑year warrants for 100,000 shares with a $0.50 exercise price was extended to September 1, 2027. Following these transactions, he directly held 653,495 common shares and 52,778 warrants.